Time to First Dose of Antibiotics in Children with Cancer and Febrile Neutropenia. A Report from a Peruvian Hospital

Ligia Rios¹*, Liliana Vasquez¹,², Ivan Maza¹, Monica Oscanoa¹, Gloria Paredes¹, Fanny Tarrillo¹, Jenny Geronimo¹

¹Pediatric Oncology Unit, Edgardo Rebagliati Hospital, Lima, Peru
²Precision Medicine Research Center, Faculty of Medicine, University of San Martin de Porres, Lima, Peru

*Corresponding author(s): Ligia Rios, Pediatric Oncology Unit, Edgardo Rebagliati Hospital, 490 Edgardo Rebagliati Avenue, Lima, Peru.

Citation: Rios L, Vasquez L, Maza I, Oscanoa M, Paredes G, et al. (2021) Time to First Dose of Antibiotics in Children with Cancer and Febrile Neutropenia. A Report from a Peruvian Hospital. Ann med clin Oncol 4: 133. DOI: 10.29011/AMCO-133.000133

Received Date: 18 October, 2021; Accepted Date: 26 October, 2021; Published Date: 29 October, 2021

Abstract

The Febrile Neutropenia (FN) in children with cancer may be the only indication of a serious underlying infection, which can lead to sepsis and be fatal; it is recommend start antibiotics as soon as possible. We realized a retrospective analysis of all patients under 14 years of age with cancer, who attended the Pediatric Emergency of Rebagliati Hospital (Lima-Peru), between July 2016 and February 2017, due to fever, neutropenia and history to received chemotherapy in the last 15 days. Of 36079 emergency attentions, 31 were episodes of FN. The median of time from arrival to emergency to the first dose of antibiotic or Time To Antibiotics (TTA) was 206 minutes (Interquartile range [IQR], 137-390). Patients with leukemia had a lower TTA than patients with solid tumors (p = 0.037). The TTA after 120 minutes was not associated with longer hospital stay, transfer to the PICU or mortality. In the cases evaluated, the TTA exceeded the international standards. Patients with solid tumors have higher TTA than patients with leukemia. It is necessary to create a multidisciplinary program to improve this time.

Keywords: Antibiotics; Children; Febrile neutropenia; Neoplasms; pediatric emergency

Abbreviations: TTA: Time From Arrival at The Emergency Room to First Dose of Antibiotics, or Time to Antibiotics.

Introduction

Cancer in the pediatric population has increased in recent years, each year more than 200 000 children are diagnosed with cancer worldwide [1], in the Americas region, more than 27 000 cases of cancer are diagnosed in children under 14 years, and an estimated 10 000 deaths are due to this disease [2]. In Peru, according to the Ministry of Health (MINSA), there are 1600 new cases per year of childhood cancer [3]. The treatment of cancer in pediatrics has three main components: surgery, radiotherapy and chemotherapy [4], which together had improved the 5-year survival less than 30% to more than 80% in the high-income countries.¹ However, like all treatment, chemotherapy has adverse effects on patients, the most important, neutropenia. This state of neutropenia causes oncology patients to be more vulnerable to severe infections, which can lead to sepsis and be fatal [5]. Fever during neutropenia induced by chemotherapy may be the only indication of a serious underlying infection, since the signs and symptoms of inflammation are usually attenuated [6]. Clinical practice guidelines, such as the Consensus of the Latin American Society of Pediatric Infectious Disease [7], emphasize the prompt institution of broad spectrum empirical antibiotic treatment, at the onset of fever, since it has been shown to be determinant for patient survival, because the progression of the infection can be rapid and cannot be reliably distinguished from fever due to other causes [8]. In Peru, no information has yet been published on this topic, so this study seeks to know the time to start treatment with antibiotics, in pediatric cancer patients, who come to the emergency department with Febrile Neutropenia (FN), and its impact on mortality, in a
referral hospital such as the Edgardo Rebagliati Martins National Hospital (HNERM).

Materials and methods

Study Design

Retrospective study. We analyzed the data obtained from the pediatric clinical records of the HNERM, in Lima-Peru.

Population

Pediatric oncology patients treated for FN, in the pediatric emergency service of the Edgardo Rebagliati Martins Hospital, between July 2016 and February 2017.

Selection Criteria

We included all cases of patients under 14 years of age, with any confirmed oncological diagnosis, who had received treatment with chemotherapy in the last 15 days before the episode of FN that attended the Pediatric Emergency. FN was defined by an absolute neutrophil count of <500 cells/mm3 or <1000 cells/mm3 if predicted to fall to <500 cells/mm3 in the next 24-48 hours, and at least one episode of fever (T °> 38 °C, taken by any method) [9]. We excluded cases where medical records were not available for review or were incomplete, cancer patients in palliative treatment or children with hematopoietic stem cells transplants.

Variables

Epidemiological information was included (sex, age, diagnosis). The following times were determined: (1) From the last day of chemotherapy until the onset of fever, (2) From the onset of fever until they reached the Pediatric Emergency, (3) Since the patient arrived at the Emergency until received the first dose of antibiotics or Time to Antibiotics (TTA). The TTA was evaluated in subcategories of time if there was re-evaluation (time from admission to emergency until the result of the blood count, from the result of the blood count to the re-evaluation, from the re-evaluation to the first dose of antibiotics). Data of hospital stay, admission to The Pediatric Intensive Care Unit (PICU) and mortality were recorded.

Statistical Analysis

The descriptive data was analyzed as median (Interquartile Range [IQR]) for continuous variables and frequency with percentages for categorical variables. The TTA was reported as a continuous variable and then as a dichotomous variable with episodes divided into the following groups according to the administration of the first dose of antibiotics: ≤120 minutes vs.>120 minutes. The other subcategories of time and hospital stay were analyzed as continuous variables. For the comparisons between 2 groups, the Fisher exact test was used for the categorical variables and the U-Mann-Whitney test was used for the medians. The final model included only significant factors (p<0.05). Statistical analyzes were performed using Stata version 14 (Stata Corp, College Station, TX).

Ethical Aspects

The protocol of this study was approved by the Ethics Committee of HNERM. The confidentiality of the data obtained from the medical records was maintained.

Results

General Description of The Population

Between July 2016 and February 2017, the Pediatric Emergency Service of HNERM performed 36079 attentions, of which 181 were attentions to pediatric patients with cancer, of these, only 31 were episodes of FN, the others 150 attentions corresponded to children with cancer with other diagnoses, such as neutropenia without fever, or fever without neutropenia, dehydration, pathological fractures, respiratory infections or palliative patients. The 31 episodes of FN corresponded to 23 patients. The median age of the 23 patients was 7 years (IQR, 4-9 years), 61% were women, and 56% were diagnosed with leukemia (Table 1).

Table 1: Characteristics of patients who attended emergency due to Febrile Neutropenia.

| Characteristics                  | N = 23 |
|----------------------------------|--------|
| Age, median (range)              | 7 years (0.5 - 13) |
| Sex:                            |        |
| Male (%)                        | 9 (39) |
| Female (%)                      | 14 (61) |
| Diagnosis:                      |        |
| Leukemia (%)                    | 13 (56) |
| Bone and soft tissue sarcomas (%)| 5 (22) |
| Brain tumors (%)                | 2 (9)  |
| Liver tumors (%)                | 2 (9)  |
| Retinoblastoma (%)              | 1 (4)  |

Table 1: Characteristics of patients who attended emergency due to Febrile Neutropenia.

Time from the onset of the fever to the start of antibiotic treatment

In the 31 episodes of FN, it was determined that the median time between the last day of chemotherapy and the onset of fever was 7 days (IQR, 4-8 days). The median time between the onset of fever until the patient arrived at the emergency service was 16 hours (IQR, 6-25 hours). The emergency physician evaluated the 100% of the patients, within 10 minutes of their arrival at the hospital. After the initial medical evaluation, 35% of the cases had an indication for antibiotic treatment, while in 65% of the cases; a blood count was requested for subsequent reassessment.
The median time from arrival at the emergency room to first dose of antibiotics or to antibiotics (TTA), in general, including both those who had only one medical evaluation and those who were reassessed, was 206 minutes (IQR, 137-390), as observed in Figure 1.

For those cases in which antibiotic was given was after the initial medical evaluation (without reassessment), the median of TTA was 119 minutes (IQR, 69-158), while for those who were reevaluated, the median of TTA 359 minutes (IQR, 211-499), being statistically significant (Mann-Whitney p = 0.0012). For the cases that were reevaluated, the subprocesses were verified (Table 2).

The TTA was significantly higher in patients with solid tumors unlike patients with leukemias (median = 388 vs 171 minutes, U. Mann-Whitney, p = 0.0374) Figure 2.

### Table 2: Time from arrival at the emergency room to first dose of antibiotics or time to antibiotics (TTA), according to the presence of reassessment.

| Subprocesses in the cases of reassessment: | N (%) | Median (minutes) | IQR (minutes) |
|------------------------------------------|-------|-----------------|---------------|
| - Time from the initial evaluation to the result of the blood count | 104 | 70 - 121 |
| - Time from laboratory result to reevaluation | 179 | 113.5 - 263 |
| - Time from re-evaluation to the first dose of antibiotic | 110 | 60 - 141 |

### Table 3: Clinical outcomes by Time from arrival at the emergency room to first dose of antibiotics or time to antibiotics (TTA).

| Time from arrival at the emergency room to first dose of antibiotics or time to antibiotics (TTA) | ≤ 120 minutes (n=6) | > 120 minutes (n=25) | p-Value |
|---------------------------------------------------------------------------------------------|---------------------|----------------------|---------|
| Days of hospital stay, median (IQR)                                                         | 16 (8-20)           | 7 (4-11)             | 0.1453* |
| Transfer to UCIP, n (%)                                                                     | 0 (0%)              | 2 (8%)               | 0.645** |
| Death, n (%)                                                                                | 1 (16.6%)           | 0 (0%)               | 0.194** |

* Value calculated by the U. Mann-Whitney test; ** Value calculated by Fisher’s exact test

### Association Between Time to Antibiotics and Clinical Outcomes

In the 31 episodes analyzed, the TTA greater than 120 minutes did not have a statistically significant relationship with the days of hospital stay, transfer to the PICU or mortality (Table 3). We also evaluated whether the diagnosis and time from the onset of fever until the patient arrived at the emergency, were related to the clinical outcomes, not finding any statistical significance, except in the days of hospital stay where patients with leukemia had a longer stay than patients with solid tumors (10.5, IQR 5.7-19 days vs. 4, IQR 5-7.5 days, p = 0.0244).
Discussion

The oncology patient’s care is multidisciplinary, and requires the joint work of both the health personnel and the family that supports the patient. This is reflected in the management of the pediatric patient, who depends on their relatives to attend their appointments, comply with the treatment or go to the emergency when is necessary [10], being of vital importance in the case of the FN, since these children have up to 1.6 times more risk of dying from sepsis than children with other diseases [11]. Neutropenia is the most serious toxicity of chemotherapy, depends on the type and dose of chemotherapy, the degree and duration of the neutropenia determine the risk of infection [12], and generally presents its nadir between 7 and 14 days after treatment, in our case we observed that the median time of onset of the fever was 7 days (IQR, 4-8). On the other hand, the Pediatric Oncology services always emphasize to their patients and relatives, the need to go to the Emergency as soon as the patient has fever, however, we see with regret in this study, that the median time since the family member perceived the fever and took the child to emergency, it was 16 hours, only 25% of patients arrived at the emergency within the first 6 hours after the fever started, this time is longer than reported in El Salvador [13], where it was 12.5 hours, as observed in a Chilean study [14], which reported a median of 2 hours.

Several guidelines [6,9,15,16], suggest to give antibiotic treatment promptly to oncologic patients with FN, multiple investigations mention that it should be initiated within the first 60 minutes of arrival at the hospital, as this has a positive impact on the evolution and survival [17-19]. Even in the study conducted by Rosa et al., in adult patients with cancer who attended emergency due to FN, they showed that each increase of 1 hour in the time of administration of antibiotic increased the mortality within the 28 days by 18% [20]. In our study we observed that although 100% of the cases of FN were evaluated by a physician within the first 10 minutes of arrival to the Emergency, the TTA was 206 minutes (IQR, 137-390), if we compare it with other Latin American studies, we see that it is very similar to that reported in El Salvador [13], whose median TTA was 210 minutes, and also in Chile [14], where the median TTA was 200 minutes. Regarding the type of cancer, we had a greater number of patients with hematological neoplasms, and we determined that those had a TTA significantly lower than the patients with solid tumors (171 vs. 388 minutes, p = 0.0374), these results are similar to those published in other studies [12], and it may be because patients with hematologic malignancies when they present to the emergency are generally clinically more unstable than patients with solid neoplasms.

It is interesting to note that countries with higher economic income had a prolonged TTA at one time. Fletcher et al. [17], conducted an investigation at the Children’s Medical Center of Dallas, between 2001 and 2009, and determined that the median TTA for oncology patients who attended in Emergency by FN was 145 minutes. On the other hand, success stories have been published, based on the implementation of multidisciplinary programs in order to reduce the TTA, for example, Volpe et al. [21], decreased the TTA from 112 to 59 minutes, demonstrating together with others studies [18,22-25], that multidisciplinary intervention programs reduce the TTA and therefore improve the quality of care and patient survival.

The impact of the TTA on clinical outcomes has been well established, Fletcher, et al. [17], research showed that the TTA after 60 minutes was associated with greater adverse events such as mortality and admission to the PICU (61-120 vs. ≤ 60 minutes, OR 1.81, 95% CI 1.01-3.26). The study by Salstrom, et al. [18], determined that the TTA within 60 minutes of arrival at the hospital significantly reduced the need for PICU (p = 0.003). However, other studies such as that of Ko, et al. [26], in Korea, where the TTA was 140 minutes (IQR, 111-180 min), showed no significant association with complications or mortality, the same was observed in the study de De la Maza, et al. [14], where a TTA> 60 minutes, was not related to an increase in the number of fever days, more transfers to the PICU or an increase in mortality. In our study we determined that there was no statistically significant relationship between the TTA was greater than 120 minutes and the days of hospital stay, transfer to PICU or mortality, this probably due to the limited number of cases.

Among the strengths of this study is to be the first to analyze the TTA in a pediatric population with cancer and FN in Peru. On the other hand, the limitations of this research are to be a retrospective study and to have a small sample, which may affect its external validation and generalization of its results.

Conclusion

In the evaluated cases the TTA for pediatric oncology patients who attend emergency due to FN, exceeds the international standards, and the patients with solid tumors have TTA longer than patients with leukemia. This study provides basic information to encourage the creation of multidisciplinary teams (emergency, oncology, nursing, laboratory, pharmacy, etc.) to improve the TTA. It is also important to emphasize the role played by family members.
in the care of these patients, and the importance of coming early in the case of fever in children with cancer. Finally, it is necessary to carry out more extensive studies on this topic in our country.

**Acknowledgment**

The author is grateful to Hemato Oncología Pediátrica del Perú Research by their support.

**References**

1. Stewart BW, Wild CP, editors (2014) World Cancer Report 2014. International Agency for Research on Cancer, France 2014.

2. OPS/OMS Perú (2017) Detección precoz del cáncer infantil será clave para disminuir la mortalidad de los niños. Cáncer Infantil, Perú 2017.

3. Ministerio de Salud del Perú (2018) Cáncer Infantil -No te tengo miedo, soy más fuerte que tú, Perú 2018.

4. Israels T, Challinor J, Howard S, Arora RH (2015) Treating Children With Cancer Worldwide—Challenges and Interventions. Pediatrics 136: 607-610.

5. Marchetti O, Calandra T (2002) Infections in neutropenic cancer patients. Lancet 359: 723-725.

6. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, et al. (2010) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52: e56-93.

7. Paganini H, Santolaya de P ME, Álvarez M, Arafía Rosainz M de J, Arteaga Bonilla R, et al. (2011) Diagnóstico y tratamiento de la neutropenia febril en niños con cáncer. Consenso de la Sociedad Latinoamericana de Infectología Pediátrica. Rev Chil Infect 28: 10-38.

8. van Vliet M, Potting CMJ, Sturm PDJ, Donnelly JP, Blijlevens NMA (2011) How prompt is prompt in daily practice? Earlier initiation of empirical antibacterial therapy for the febrile neutropenic patient. Eur J Cancer Care (Engl) 20: 679-685.

9. Bate J, Chisholm R (2014) Treatment of infections in the neutropenic or immunosuppressed patient. In: Cheng D, Tattermusch S (Editors). Paediatric Haematology & Oncology: Supportive Care Protocol. (4th edition), NHS Foundation Trust, London, England 2014: 29-44.

10. Sung L, Phillips R, Lehrnbecher T (2011) Time for paediatric febrile neutropenia guidelines - children are not little adults. Eur J Cancer 47: 811-813.

11. Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M, et al. (1997) A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. Br J Haematol 99: 580-588.

12. Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia. Cancer 100: 228-237.

13. Gavidia R, Fuentes SL, Vasquez R, Bonilla M, Ethier MC, et al. (2012) Low Socioeconomic Status Is Associated with Prolonged Times to Assessment and Treatment, Sepsis and Infectious Death in Pediatric Fever in El Salvador. PLoS One 7: e43639.